Relmada Therapeutics, Inc. RLMD Payments Of Stock Issuance Costs
Payments Of Stock Issuance Costs at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s payments of stock issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s payments of stock issuance costs?
- Relmada Therapeutics, Inc. (RLMD) reported payments of stock issuance costs of $65.65K in Q1 2026.
- How has Relmada Therapeutics, Inc.'s payments of stock issuance costs changed year-over-year?
- Relmada Therapeutics, Inc.'s payments of stock issuance costs increased by 259.6% year-over-year, from $18.26K to $65.65K.
- What is the long-term trend for Relmada Therapeutics, Inc.'s payments of stock issuance costs?
- Over 2 years (2023 to 2025), Relmada Therapeutics, Inc.'s payments of stock issuance costs has grown at a -13.9% compound annual growth rate (CAGR), from $98.46K to $73.02K.
- What does payments of stock issuance costs mean?
- Direct costs incurred in connection with the issuance of common stock, such as legal, accounting, and underwriting fees. These costs represent the friction associated with raising capital from public or private equity markets.